clinical trial · NCT05813327
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Soft Tissue SarcomaStsSarcoma,Soft TissueADI PEG20IfosfamideRadiotherapyMesna
brief summary
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.
started
Mar 14, 2024
primary completion
Apr 10, 2026
completion
Jul 22, 2026
last updated
Apr 20, 2026
official title
A Phase I/II Trial of Neoadjuvant ADI-PEG 20 in Combination With Ifosfamide and Radiotherapy in Soft Tissue Sarcoma (STS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol